AstraZeneca has received Food And Drug Administration approval for one product, and entered into a deal to sell the U.S. rights to another. The FDA granted marketing approval to Bevespi Aerosphere, a maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.